Stroke Trial, Recruiting NCT07115940 Sponsor: Amrou Sarraj Condition: Stroke
Back to Stroke

Stroke Trial, Recruiting

NCT07115940
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 to 85 years (up to but not including their 86th birthday) who have been diagnosed with an acute ischemic stroke (a stroke caused by a blockage)
  • People whose stroke symptoms score at least 6 on a standard medical severity scale (NIHSS), indicating a moderate to severe stroke
  • People who are between 24 and 72 hours past the time they were last known to be well before their stroke was noticed
  • People who were fully independent or had only very minor disability before their stroke (pre-stroke modified Rankin Scale score of 0–1)
  • People who are considered suitable for both a clot-removal procedure (thrombectomy) and standard medical treatment
  • People who have signed a consent form agreeing to participate
  • People who are willing to attend all required follow-up visits as set out in the study plan
  • People who are expected to live for at least 3 months
  • People whose brain scans show a blockage in one of the large blood vessels supplying the brain (the internal carotid artery or the main middle cerebral artery), confirmed by specialised scan imaging (MRA or CTA)
  • People whose brain scan score (CT ASPECTS) falls between 3 and 10, indicating that not too much brain tissue has already been damaged
  • People whose brain scans show that the area of severely damaged brain tissue is 150 ml or less in volume, measured using specific perfusion or diffusion imaging methods

Who may not be able to join:

  • People who are currently taking part in another clinical trial involving an experimental drug or medical device
  • People whose blood platelet count is below 100,000/μl (platelets are cells that help blood clot)
  • People whose brain scans show a tumour (except a small, non-inflamed meningioma under 3 cm), any active bleeding in the brain, or an abnormal tangle of blood vessels (arteriovenous malformation)
  • People whose brain scans show significant shifting of brain structures to one side (midline shift greater than 3 mm) or signs of swelling pressing on the opposite side of the brain
  • People with evidence of a tear in the internal carotid artery that is blocking blood flow, or a tear in the main artery leaving the heart (aorta)
  • People who have a previously placed stent inside the brain in the same area as the blockage, which could make the clot-removal procedure unsafe
  • People who have blockages in more than one separate brain artery at the same time (for example, blockages in both sides of the brain, or in two different major arteries)
  • People whose brain scans already show a clearly established area of dead brain tissue or swelling on standard CT imaging
  • People whose brain scan score (CT ASPECTS) is 0, 1, or 2, indicating very extensive early brain damage
  • People whose brain scans show that the area of severely damaged brain tissue is greater than 150 ml in volume
  • People who had a stroke while already in hospital and whose symptoms were fluctuating, if they first presented to the hospital within 24 hours of when they were last known to be well (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Amrou Sarraj, MD, University Hospitals

Phone: 216-286-6458

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Amrou Sarraj
Registry
ClinicalTrials.gov
Start date
13 April 2026
Est. completion
1 November 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

The distribution of the modified Rankin Scale score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov